# Capricorn Partners

> Capricorn Partners is a VC fund backing Biotechnology and Health Care. See 120 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Leuven, Belgium
- Total investments: 120
- Last investment: Jul 2026
- Lead investor: 33%
- Last fund: Jan 2025
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/1533321?trk=tyah&trkInfo=clickedVertical%3Acompany%2CclickedEntityId%3A1533321%2Cidx%3A1-1-1%2CtarId%3A1444054150240%2Ctas%3Acapricorn%20venture
- Website: http://www.capricorn.be

Capricorn Partners is a VC fund in Leuven focused on Biotechnology and Health Care. Capricorn Partners NV is an independent pan-European manager of venture capital funds that invest in innovative European companies with technology as a competitive advantage. The investment team of Capricorn is composed of experienced investment managers with deep technology expertise and broad industrial experience.As of Dec 2010

## Contacts

5 contacts available for Capricorn Partners. Shizune tracks 9 team members at Capricorn Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/capricorn-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $3.3M–$18M |
| Series B | $5.3M–$42M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 22 | 18% |
| Health Care | 17 | 14% |
| Software | 16 | 13% |
| Manufacturing | 11 | 9% |
| Medical Device | 11 | 9% |

124 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 25 | 21% |
| Series B | 23 | 19% |
| Funding Round | 23 | 19% |
| Seed | 12 | 10% |
| Series C | 9 | 8% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 30 | 25% |
| The Netherlands | 14 | 12% |
| United States | 13 | 11% |
| Germany | 8 | 7% |
| France | 4 | 3% |

13 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Katrin Geyskens | Partner | 8 | https://shizune.co/investors/profile/katrin-geyskens |
| Marc Lambrechts | Investment Director | 4 | https://shizune.co/investors/profile/marc-lambrechts |
| Rob van der Meij | Investment Manager | 3 | https://shizune.co/investors/profile/rob-van-der-meij |
| Steven Lambert | Sr. Investment Manager | 4 | https://shizune.co/investors/profile/steven-lambert |
| Filip Pintelon | Investment Partner | 1 | https://shizune.co/investors/profile/filip-pintelon |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Endo Tools Therapeutics | Endo Tools Therapeutics (ETT) is a privately held medical device company in Brussels Belgium, that was established in October 2008. The company is dedicated to the development of innovative devices providing new means of therapeutic interventions for gastroenterologists.ETT is currently developing a catheter that will add therapeutic channelsand degrees of freedom for interventional gastro-enterology. | $22.9M | Venture - Series Unknown | Jul 16, 2026 |  |
| Trillium Renewable Chemicals | Trillium Renewable Chemicals manufactures chemicals from renewable feedstocks used in a variety of industrially important applications. The company was founded in 2021 and based in Knoxville, Tennessee. | $13M | Series B | May 05, 2026 |  |
| Trillium Renewable Chemicals | Trillium Renewable Chemicals manufactures chemicals from renewable feedstocks used in a variety of industrially important applications. The company was founded in 2021 and based in Knoxville, Tennessee. | $13M | Series B | May 05, 2026 |  |
| ROCSYS | ROCSYS develops solutions to fully automate professional charging sites. With its smart solutions, EV infrastructure operators can increase their asset utilization. This allows fleet operators to run business critical operations with EVs and additionally prepare for the self-parking and self-driving era. ROCSYS’ solutions are based on proprietarypatented soft-robotics technologies, complemented with a suite of remote management and support tools, and an API integration platform, enabling a complete solution to serve growing industry needs. | $13M | Series A | Apr 29, 2026 |  |
| CONXAI | CONXAI develops a no-code artificial intelligence platform designed to automate knowledge-intensive workflows in the architecture, engineering, and construction industries. The company enables organizations to transform fragmented project data, documents, and tacit human expertise into structured, actionable insights that support decision-makingand operational efficiency. Its platform uses smart AI and systems with multiple agents to look at different types of data like documents, images, and project records, so users can create and use AI solutions without needing to know how to code. These capabilities support tasks like project monitoring, risk assessment, and workflow automation across complex construction environments.CONXAI focuses on addressing challenges related to siloed data and undocumented knowledge in construction projects, where critical information is often dispersed across tools and stakeholders. By integrating and contextualizing this data, the platform enables improved collaboration, visibility, and control throughout the project lifecycle. | $5.8M | Series A | Apr 07, 2026 |  |
| Oska Health | Oska Health delivers digital-enabled care solutions for chronic kidney disease patients, a top clinical need for healthcare payers. By leveraging evidence-based medical best practices and behavioral science, Oska Health aims to empower individuals with kidney disease to mitigate their risk of cardiovascular complications and kidney failure whilesimultaneously lowering costs of care. The company partners with healthcare payers to provide a comprehensive solution that includes a personal coach, a state-of-the-art health app, and intelligent treatment plan algorithms, all designed to help individuals establish new routines and achieve optimal health outcomes. | $13M | Seed | Feb 26, 2026 |  |
| Xyall | Xyall is a global innovator in molecular pathology. | $9M |  | Feb 11, 2026 |  |
| Trendtracker | Trendtracker is an innovative AI-powered strategic and foresight intelligence tool. | $6.9M | Series A | Dec 10, 2025 |  |
| Azumuta | Azumuta is the most complete software tool that eliminates the use of paperwork in your factory. From digital work instructions to frontline communication, data analysis, and IoT connection. | $9.3M | Series A | Nov 13, 2025 |  |
| Aspect Analytics | Aspect Analytics offers consultancy services, home-grown software, development of workflows, and customization of software. | $11.7M | Series A | Sep 09, 2025 |  |

10 of 120 investments shown.

## Co-investors
- [Quest for Growth](https://shizune.co/investors/profile/quest-for-growth) — VC Fund, 13 deals together
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund, 12 deals together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 6 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 6 deals together
- [Oxford Capital](https://shizune.co/investors/profile/oxford-capital-partners) — VC Fund, 5 deals together
- [SFPI-FPIM](https://shizune.co/investors/profile/sfpi-fpim) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [All Investors in Belgium](https://shizune.co/investors/investors-belgium)
- [All VC Funds in Belgium](https://shizune.co/investors/vc-funds-belgium)
- [SaaS Investors in Belgium](https://shizune.co/investors/saas-investors-belgium)
- [SaaS VC Funds in Belgium](https://shizune.co/investors/saas-vc-funds-belgium)
- [Software VC Funds in Belgium](https://shizune.co/investors/software-vc-funds-belgium)
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)

## FAQ

### What does Capricorn Partners invest in?

Capricorn Partners invests primarily in Biotechnology, Health Care and Software startups, most often at Series A and Series B stage. Most of the 120 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Capricorn Partners's check size?

Capricorn Partners typically joins rounds of $3.3M–$18M at Series A and $5.3M–$42M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Capricorn Partners participates in.

### How do I contact Capricorn Partners?

Public channels for Capricorn Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Capricorn Partners?

The team at Capricorn Partners includes Katrin Geyskens (Partner), Marc Lambrechts (Investment Director) and Rob van der Meij (Investment Manager), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co